Study of SU5416 in Cancer Treatment
Author Information
Author(s): O'Donnell A, Padhani A, Hayes C, Kakkar A J, Leach M, Trigo J M, Scurr M, Raynaud F, Phillips S, Aherne W, Hardcastle A, Workman P, Hannah A, Judson I
Primary Institution: Institute of Cancer Research, Sutton, UK
Hypothesis
Can SU5416 effectively inhibit angiogenesis in solid tumors?
Conclusion
SU5416 was well tolerated but did not show significant changes in tumor vascular permeability or treatment-related changes in VEGF levels.
Supporting Evidence
- SU5416 was administered to 27 patients with solid tumors.
- The drug was well tolerated, with no maximum-tolerated dose defined.
- Dynamic contrast-enhanced MRI did not show significant changes in vascular permeability.
- VEGF levels did not show statistically significant treatment-related changes.
Takeaway
Doctors tested a new drug called SU5416 to see if it could help treat cancer by stopping the growth of blood vessels that feed tumors, but it didn't work as well as hoped.
Methodology
Patients with treatment refractory solid tumors received SU5416 via intravenous infusion twice weekly, and various assessments were made including DCE-MRI and VEGF levels.
Potential Biases
Potential bias due to the small sample size and the nature of the patient population with advanced disease.
Limitations
The study had a small sample size and did not include internal reproducibility data for the study population.
Participant Demographics
14 males and 14 females, median age 48 years (range 18–74 years).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website